BR112021026663A2 - Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal - Google Patents
Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatalInfo
- Publication number
- BR112021026663A2 BR112021026663A2 BR112021026663A BR112021026663A BR112021026663A2 BR 112021026663 A2 BR112021026663 A2 BR 112021026663A2 BR 112021026663 A BR112021026663 A BR 112021026663A BR 112021026663 A BR112021026663 A BR 112021026663A BR 112021026663 A2 BR112021026663 A2 BR 112021026663A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- neonatal
- receptor
- psma
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal.a invenção se refere a anticorpos anti-psma compreendendo uma região constante da cadeia pesada compreendendo uma ou mais substituições de aminoácidos em comparação com uma igg de tipo selvagem, em que a uma ou mais substituições de aminoácidos reduzem a afinidade do anticorpo para o receptor fc neonatal (fcrn), reduzindo assim a meia-vida sérica do anticorpo modificado em comparação com um anticorpo de tipo selvagem da classe igg. a uma ou mais modificações de aminoácidos tendo o efeito de reduzir a ligação de fcrn são selecionadas a partir das posições his310, his433, his435, his436, ile253. os anticorpos da presente invenção são particularmente adequados para uso em radioimunoterapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019902344A AU2019902344A0 (en) | 2019-07-02 | Antibodies | |
PCT/AU2020/050690 WO2021000018A1 (en) | 2019-07-02 | 2020-07-02 | Antibodies for binding psma with reduced affinity for the neonatal fc receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021026663A2 true BR112021026663A2 (pt) | 2022-04-12 |
Family
ID=74100117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021026663A BR112021026663A2 (pt) | 2019-07-02 | 2020-07-02 | Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220323619A1 (pt) |
EP (1) | EP3994177A4 (pt) |
JP (1) | JP2022540385A (pt) |
KR (1) | KR20220057517A (pt) |
CN (1) | CN114555641A (pt) |
AU (1) | AU2020299025A1 (pt) |
BR (1) | BR112021026663A2 (pt) |
CA (1) | CA3141471A1 (pt) |
CL (1) | CL2021003563A1 (pt) |
IL (1) | IL289523A (pt) |
MA (1) | MA56469A (pt) |
MX (1) | MX2021015669A (pt) |
WO (1) | WO2021000018A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023028654A1 (en) * | 2021-09-01 | 2023-03-09 | Telix International Pty Ltd | Aggregate separation method |
EP4279092A1 (en) | 2022-05-17 | 2023-11-22 | Bayer AG | Radiopharmaceutical complexes targeting prostate-specific membrane antigen |
WO2023222557A1 (en) | 2022-05-17 | 2023-11-23 | Bayer Aktiengesellschaft | Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2632094C (en) * | 2005-12-02 | 2015-01-27 | Wayne A. Marasco | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
SG10201800492PA (en) * | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
TWI653243B (zh) * | 2013-04-29 | 2019-03-11 | 赫孚孟拉羅股份公司 | 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途 |
JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
US11254744B2 (en) * | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
EP4282434A3 (en) * | 2016-06-06 | 2024-03-06 | Abzena (UK) Limited | Antibodies, uses thereof and conjugates thereof |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
-
2020
- 2020-07-02 CA CA3141471A patent/CA3141471A1/en active Pending
- 2020-07-02 WO PCT/AU2020/050690 patent/WO2021000018A1/en active Application Filing
- 2020-07-02 EP EP20835081.9A patent/EP3994177A4/en active Pending
- 2020-07-02 AU AU2020299025A patent/AU2020299025A1/en active Pending
- 2020-07-02 US US17/622,333 patent/US20220323619A1/en active Pending
- 2020-07-02 MX MX2021015669A patent/MX2021015669A/es unknown
- 2020-07-02 MA MA056469A patent/MA56469A/fr unknown
- 2020-07-02 BR BR112021026663A patent/BR112021026663A2/pt unknown
- 2020-07-02 CN CN202080054212.1A patent/CN114555641A/zh active Pending
- 2020-07-02 JP JP2021578269A patent/JP2022540385A/ja active Pending
- 2020-07-02 KR KR1020227002845A patent/KR20220057517A/ko unknown
-
2021
- 2021-12-29 CL CL2021003563A patent/CL2021003563A1/es unknown
- 2021-12-30 IL IL289523A patent/IL289523A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220323619A1 (en) | 2022-10-13 |
CN114555641A (zh) | 2022-05-27 |
EP3994177A4 (en) | 2023-09-20 |
MX2021015669A (es) | 2022-04-18 |
CA3141471A1 (en) | 2021-01-07 |
IL289523A (en) | 2022-03-01 |
JP2022540385A (ja) | 2022-09-15 |
CL2021003563A1 (es) | 2022-11-18 |
EP3994177A1 (en) | 2022-05-11 |
MA56469A (fr) | 2022-05-11 |
WO2021000018A1 (en) | 2021-01-07 |
KR20220057517A (ko) | 2022-05-09 |
AU2020299025A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021026663A2 (pt) | Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal | |
CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
BRPI0611714A2 (pt) | proteÍnas de ligaÇço a il-12/p40 | |
BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
BRPI0716438A8 (pt) | Proteínas ligantes interleucina-1,3 | |
BRPI0507433C1 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
BR112012006492A2 (pt) | proteína de fusão de anticorpo multivalente, e, ligação de albumina | |
BR112022014771A2 (pt) | Anticorpo anti-receptor de transferrina (tfr) e usos do mesmo | |
PE20121129A1 (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana | |
CY1118420T1 (el) | Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
BRPI0716811B8 (pt) | anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases | |
EA201291181A1 (ru) | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
BR0308585A (pt) | Anticorpos anti-alfavbeta6 | |
BR112021026651A2 (pt) | Anticorpos contra caix com afinidade reduzida para o receptor fc neonatal | |
CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
BR112017019191A2 (pt) | métodos para reduzir níveis de soro de agentes que contêm fc utilizando antagonistas de fcrn | |
BR112015008663A2 (pt) | proteínas imunomodulatórias | |
BRPI0410261B8 (pt) | anticorpo monoclonal que se liga especificamente ao probnp, métodos para detecção específica de probnp in vitro e para diagnóstico de insuficiência cardíaca in vitro, kit para medição de probnp, e linhagem celular de hibridoma mab 1.21.3 | |
NO20076568L (no) | Anti-IL2 antistoffer | |
Kellett-Clarke et al. | CD44 binding to hyaluronic acid is redox regulated by a labile disulfide bond in the hyaluronic acid binding site | |
BRPI0507019A (pt) | composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su | |
BR112021026089A2 (pt) | Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos | |
BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento |